In 2020, the overall share of the Global Endovascular Aneurysm Repair (EVAR) Market was USD 2.87 Bn. The Endovascular Aneurysm Repair (EVAR) Market is prevised to reach USD 4.26 Bn by 2030, with a robust CAGR of 5.8 percent throughout the prevised period of 2020-2030. The overall procedure of Endovascular aneurysm repair (EVAR) is a vital advancement in the treatment of abdominal aortic aneurysm (AAA). EVAR is primarily performed by injecting graft components which are mainly folded and compressed through a delivery sheath within the lumen of an access vessel. In comparison with the open AAA repair, the overall EVAR procedure is linked with a significant reduction in perioperative mortality, primarily because EVAR doesn’t need any sort of operative exposure of the aorta / aortic clamping. Moreover, the Aortic repair devices that are used in the treatment of Endovascular aneurysm repair (EVAR) procedures are medical devices that are primarily utilized in the curing, maintenance, and longevity of the aortic systems in human beings. Also, these devices are highly used in curing various endovascular disorders, such as aneurysms and many other conditions.
To know more about the report, Click on the link https://www.strategicmarketresearch.com/market-report/endovascular-aneurysm-repair-market
Crucial aspects responsible for the growth of the market
Some of the crucial aspects that enhance the growth of the endovascular aneurysm repair market are the increase in the occurrences of aortic aneurysms, the surge in the old age population, technical growth in the EVAR procedures, wide availability of various favorable reimbursements policies for EVAR procedures & devices and the rise in the smoking population.
The North American market for Endovascular Aneurysm Repair held the largest share of the market
On a regional scale, the ‘North America’ segment contains the highest share of the market. Due to the growth of modern innovative medical technologies in this region, it is expected to continue its leading position in the upcoming future. Also, in the year 2020, the region Asia-Pacific and Latin America together both had accounted for about 18 percent of the entire market. It is because of the rising endovascular aneurysm repairs, especially in China, India, and other growing countries. The enlargement of the market in the Asia-Pacific region is mostly due to a rise in the geriatric population.
Competitive Landscape
Various significant organizations have done various mergers and acquisitions, and hence they have prepared new products to fulfill the overall demand for the EVAR processes and equipment. Also, various products related to the EVAR market are prevised to grow at a steady CAGR of about 6.9 percent throughout the entire timeframe. It is due to the increasing demand for various advanced techniques, the rise in the occurrence of the aneurysm, and the quick growth in the elderly population across the globe. This opens up new growth opportunities for all the manufacturers in the EVAR space. Therefore, it is for this reason that all the leading companies are nurturing their next-generation EVAR products in terms of innovating, developing, and creating a good momentum to excel in the market forward. Some of the leading major players that are associated in the market of Endovascular Aneurysm Repair are Gamida Cell Ltd., Cook Group Incorporated, Lombard Medical Limited, Bolton Medical Inc., Shanghai MicroPort Medical (Group) Co. Ltd., JOTEC GmbH, W. L. Gore & Associates Inc., Getinge AB (Maquet), Medtronic plc, Cardinal Health, Terumo Corporation, Endologix Inc.,
Latest Developments
The GORE® EXCLUDER® Conformable AAA Endoprosthesis embedded with ACTIVE CONTROL System is regarded as a next-generation EVAR (Endovascular Aneurysm Repair) device that is specially framed for the treatment of abdominal aortic aneurysms (AAA) among the individuals with difficult anatomy. Also, the market successfully had established an effective method for the approval of the Zenith Dissection Endovascular System. This device constitutes an intermediate stent-graft element along with a distal bare stent component, thus giving the physicians a less invasive alternative to open surgery for curing the Type B descending thoracic aorta dissections.